Current evidence and strategies for bridging therapy in CD19-directed chimeric antigen receptor T-cell therapy for

Jie Lv1, Yan Xie1, Chen Zhang1

  • 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Annals of Hematology
|March 23, 2026
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos